Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Worldwide, over 10 million individuals suffer from drug-resistant epilepsy. New therapeutic strategies are needed to address this debilitating disease. Inhibition of sodium-glucose linked transporters (SGLTs), which are variably expressed in the brain, has been demonstrated to reduce seizure activity in murine models of epilepsy. Here we investigated the effects of dapagliflozin, a highly competitive SGLT2 inhibitor currently used as a drug for diabetes mellitus, on seizure activity in rats with pentylenetetrazol (PTZ) induced seizures. METHODS: Laboratory rats (n = 48) were evenly randomized into two experiments, each with four study arms: (1) a vehicle-treated (placebo) arm infused with saline; (2) a control arm infused with PTZ; (3) a treatment arm with PTZ and dapagliflozin at 75 mg/kg, and (4) another treatment arm with PTZ and dapagliflozin at 150 mg/kg. Study subjects were assessed for seizures either via EEG as measured by spike wave percentage (SWP), or clinically via Racine's scales scores (RSS) and time to first myoclonic jerk (TFMJ). RESULTS: Rats treated with dapagliflozin had lower mean SWP on EEG (20.4% versus 75.3% for untreated rats). Behaviorally, treatment with dapagliflozin improved means RSS (2.33 versus 5.5) and mean TFMJ (68.3 versus 196.7 s). All of these findings were statistically significant with p-values of < 0.0001. There was a trend towards even better seizure control with the higher dose of dapagliflozin at 150 mg/kg, however this was not consistently statistically significant. CONCLUSIONS: Dapagliflozin decreased seizure activity in rats with PTZ-induced seizures. This may be explained by the anti-seizure effects of decreased glucose availability and a reduction in sodium transport across neuronal membranes which can confer a stabilizing effect against excitability and unwanted depolarization. The potential clinical role of dapagliflozin and other SGLT2 inhibitors as anti-seizure medications should be further explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“based on the results obtained by Erdogan MA. et al., Dapagliflozin significantly reduces seizure activity, both at the electrophysiological and clinical level, in a rat model of epilepsy [32].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [32]
In the citing paper
“However, SGLT-2 plays a role in other functions in CNS besides glucose transport.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AChE-stained horizontal sections of the rat brain in stereotaxic coordinates
Paxinos, G., Watson, C. R. R., & Emson, P. C. (1980) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(80)90021-7 · Cited by 4,497 · cited 1×
“5 mm posterior to the lambda, along the midline [13, 14].”
BackgroundThe ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial
Neal, E. G., Chaffe, H., Schwartz, R. H., Lawson, M. S., Edwards, N., Fitzsimmons, G., Whitney, A., & Cross, J. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70092-9 · Cited by 1,224 · cited 3×
“The augmentation of glucose transport and metabolism, typically by limiting its availability and encouraging the brain to rely on other substrates for energy such as ketones, is a strategy that has been proven to control certain seizure disorders, including treatment-intractable epilepsy in children [24].”
BackgroundMethodInfluentialMoshé, S. L., Perucca, E., Ryvlin, P., & Tomson, T. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60456-6 · Cited by 905 · cited 2×
“It is estimated that approximately 2 million people in the United States have epilepsy [1].”
BackgroundRenal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583 · cited 3×
“Sodium–glucose linked transporters (SGLTs) are transcribed from genes that belong to the solute carrier 5A (SLC5A) family of genes, which harness the gradient of sodium ions across the plasma membrane to drive glucose and galactose into cells [6, 20, 21].”
BackgroundThe sodium/glucose cotransport family SLC5
Wright, E. M., & Turk, E. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1202-0 · Cited by 537 · cited 2×
“With regards to the SGLTs, these transporters were first identified in the intestine and kidney [6, 7].”
BackgroundFunctional expression of sodium-glucose transporters in cancer
Scafoglio, C., Hirayama, B. A., Kepe, V., Liu, J., Ghezzi, C., Satyamurthy, N., Moatamed, N. A., Huang, J., Koepsell, H., Barrio, J. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511698112 · Cited by 329 · cited 1×
“Sodium–glucose linked transporters (SGLTs) are transcribed from genes that belong to the solute carrier 5A (SLC5A) family of genes, which harness the gradient of sodium ions across the plasma membrane to drive glucose and galactose into cells [6, 20, 21].”
BackgroundFacilitated Hexose Transporters: New Perspectives on Form and Function
Manolescu, A. R., Witkowska, K., Kinnaird, A., Cessford, T., & Cheeseman, C. (2007) · Physiology · doi:10.1152/physiol.00011.2007 · Cited by 235 · cited 1×
“Glucose transporters (GLUTs) exist in two major groups: [1] the GLUT energy-independent facilitated transporters [4]; and [2] the SGLT sodium-glucose linked transporters.”
BackgroundRovet, J. F., & Ehrlich, R. M. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70211-8 · Cited by 220 · cited 1×
“This is an often-feared adverse effect of antidiabetic drugs such as insulin and sulfonylureas [27].”
BackgroundAeby, A., Poznanski, N., Verheulpen, D., Wetzburger, C., & Van Bogaert, P. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00337.x · Cited by 158
Cellular localization and characterization of Glut 3 glucose transporter isoform in human brain
Mantych, G. J. (1992) · Endocrinology · doi:10.1210/en.131.3.1270 · Cited by 146 · cited 1×
“While glucose transporter 1 (GLUT1) is the predominant isoform expressed in the BBB and glial cells [18], glucose transporter 3 (GLUT3) is the dominant isoform expressed in neurons [19].”
Background
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“Anti-epileptic Potential n/a n/a Yes [32] n/a /”
BackgroundInfluentialCognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Rizzo, M. R., Di Meo, I., Polito, R., Auriemma, M. C., Gambardella, A., di Mauro, G., Capuano, A., & Paolisso, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106062 · Cited by 178
Arab, H. H., Safar, M. M., & Shahin, N. N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00722 · Cited by 178
Arab, H. H., Al‐Shorbagy, M. Y., & Saad, M. A. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109368 · Cited by 152
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 148
Metadata
- Authors
- Erdogan, M. A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., & Erbas, O.
- Affiliations
- University of Alberta (CA)
- Simon Fraser University (CA)
- Trakya University (TR)
- Corresponding author
- Christy, Joanna
- Venue
- BMC Neurology
- Published
- 2018-06-07
- Volume
- 18
- Issue
- 1
- Pages
- 81-81
- ISSN
- 1471-2377 (ISSN-L)
- PMC
- PMC5991447
- OpenAlex
- W2805363895
- Cited by
- 87
- References
- 31
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 9 · 2023: 16 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 1
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Neurology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Istanbul Science University (Istanbul Bilim University) (submittedVersion, other-oa)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Summit (Simon Fraser University) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- dapagliflozin, SGLT2 inhibitors, drug-resistant epilepsy, pentylenetetrazole-induced seizures, antiseizure effects, glucose availability, sodium transport, myoclonic jerks
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Benzhydryl Compounds, Disease Models, Animal, Epilepsy, Glucosides, Random Allocation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. https://app.cochat.ai/papers/10.1186/s12883-018-1086-4
- The paper
- Erdogan, M. A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., & Erbas, O. (2018). Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurology. https://doi.org/10.1186/s12883-018-1086-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.